Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Mizuho Markets Americas LLC

Mizuho Markets Americas LLC boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 22.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 399,065 shares of the biotechnology company's stock after purchasing an additional 72,765 shares during the period. Sarepta Therapeutics makes up approximately 1.0% of Mizuho Markets Americas LLC's holdings, making the stock its 22nd largest position. Mizuho Markets Americas LLC owned about 0.42% of Sarepta Therapeutics worth $49,839,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of SRPT. Innealta Capital LLC bought a new stake in Sarepta Therapeutics during the second quarter valued at about $31,000. New Covenant Trust Company N.A. purchased a new position in shares of Sarepta Therapeutics during the first quarter valued at about $32,000. Nkcfo LLC purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at about $43,000. Huntington National Bank grew its position in shares of Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 175 shares in the last quarter. Finally, Riggs Asset Managment Co. Inc. grew its position in shares of Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 75 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

Analyst Ratings Changes

Several research analysts recently commented on SRPT shares. Jefferies Financial Group started coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They issued a "buy" rating and a $165.00 price target for the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Robert W. Baird dropped their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a research report on Thursday, November 7th. Raymond James reiterated an "outperform" rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Finally, Guggenheim lifted their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. One analyst has rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $181.33.

Insiders Place Their Bets

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. This represents a 14.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT traded down $4.57 during mid-day trading on Friday, hitting $104.54. The company's stock had a trading volume of 1,571,012 shares, compared to its average volume of 1,234,834. Sarepta Therapeutics, Inc. has a 1 year low of $78.67 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock has a market cap of $9.99 billion, a price-to-earnings ratio of 83.63 and a beta of 0.81. The business's fifty day moving average is $123.72 and its two-hundred day moving average is $132.33.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.